News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Abivax
< Previous
1
2
3
Next >
Abivax Announces Closing of $747.5 Million Public Offering
July 28, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
July 25, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
July 24, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax announces trading resumption of its ordinary shares on Euronext Paris
July 24, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
July 24, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Launch of Public Offering
July 23, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
July 22, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Results of its June 6, 2025 Annual General Meeting
June 11, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Presents First Quarter 2025 Financial Results
June 02, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
April 29, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
April 22, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
April 22, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
March 26, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Full Year 2024 Financial Results
March 24, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
February 21, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Publishes 2025 Financial Calendar
January 28, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
January 23, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
January 09, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces a Change to the Composition of its Board of Directors
December 23, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
November 19, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax presents third quarter 2024 key financial information
November 14, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
November 13, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
October 07, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
October 03, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
October 03, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
September 26, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
September 25, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax presents first-half 2024 financial results
September 09, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
August 06, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Provides Operational and Key Program Update
July 15, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
